F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comJubilant Pharmova Ltd is a well-known pharmaceutical and life sciences company in India, engaged in contract research, development, and manufacturing. Over the years, the company has built a strong presence in the global pharma space with its focus on innovation, quality, and sustainability. In this blog, we’ll explore Jubilant Pharmova’s share price targets from 2025 to 2030, while also analyzing its financials, shareholding pattern, and long-term growth potential.
Let’s take a closer look at Jubilant Pharmova’s business fundamentals and future stock projections.
| Detail | Value |
|---|---|
| Current Price | ₹1,067.00 |
| Previous Close | ₹1,066.80 |
| Day's High | ₹1,077.40 |
| Day's Low | ₹1,055.00 |
| VWAP | ₹1,065.26 |
| 52-Week High | ₹1,309.90 |
| 52-Week Low | ₹802.00 |
| All-Time High | ₹1,309.90 |
| All-Time Low | ₹3.48 |
| Market Capitalization | ₹17,106 Cr |
| Beta (Volatility) | 0.84 |
| Book Value Per Share | ₹372.96 |
| Face Value | ₹1 |
| Dividend Yield | 0.47% |
| Average 20D Volume | 3,50,330 |
| Average Delivery (20D) | 42.04% |
Jubilant Pharmova Ltd operates in pharmaceuticals, contract development and manufacturing services (CDMO), and specialty chemicals. The company has a global footprint with clients across North America, Europe, and Asia. Its strong R&D capabilities, API manufacturing, and partnerships with leading pharmaceutical companies make it a significant player in the sector.
Strong focus on innovation and new drug development.
Stable business model with diversified revenue streams.
Significant global presence across regulated markets.
Strong financial discipline and moderate dividend payout.
Volatility (Beta: 0.84) indicates relatively stable stock performance compared to the market.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 47.68% |
| Retail & Others | 25.39% |
| Foreign Institutions | 17.40% |
| Mutual Funds | 6.01% |
| Other Domestic Institutions | 3.52% |
This shareholding pattern reflects a balanced mix of promoters, retail, and institutional investors, showing overall confidence in the company’s growth prospects.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 1,100 | 1,180 |
| 2026 | 1,250 | 1,350 |
| 2027 | 1,400 | 1,520 |
| 2028 | 1,550 | 1,700 |
| 2029 | 1,700 | 1,900 |
| 2030 | 1,900 | 2,200 |
By 2025, Jubilant Pharmova is expected to maintain stability in its revenue due to steady demand for APIs and CDMO services.
Why?
Stable global pharma demand.
Improved operational efficiency.
Strong promoter holding ensures confidence.
Investment Advice: Consider staggered investments during market dips.
The company is likely to see higher revenue from contract research and specialty chemicals.
Why?
Expansion in regulated markets.
New product launches in pharma and life sciences.
Better R&D spending.
Investment Advice: Hold the stock for medium-term gains.
By 2027, Jubilant could benefit from its global partnerships and innovation pipeline.
Why?
Increasing exports to North America and Europe.
Demand for specialty drugs.
Growth in CDMO contracts.
Investment Advice: Reinvest dividends for compounding returns.
In 2028, Jubilant is expected to cross the ₹1,600 mark comfortably.
Why?
Strong earnings growth.
Expanding product basket.
Increased demand for generic drugs.
Investment Advice: Suitable for long-term portfolios with moderate risk appetite.
By 2029, Jubilant may become a stronger global player.
Why?
Sustainable revenue growth in all business segments.
Institutional investors increasing stake.
Growing demand in emerging markets.
Investment Advice: Good option for medium- to long-term investors.
By 2030, Jubilant Pharmova could achieve multi-year highs, making it a strong wealth creator.
Why?
Leadership in CDMO and specialty pharma.
Expanding presence in global regulated markets.
Solid financials and consistent EPS growth.
Investment Advice: Excellent choice for long-term investors looking at healthcare sector growth.
Yes. Jubilant Pharmova is a fundamentally strong company with consistent revenue streams, a diversified business model, and a stable promoter holding.
Global presence in pharma and specialty chemicals.
Strong R&D and innovation focus.
Relatively stable stock with low Beta.
Regular dividends, though modest.
Global regulatory challenges.
Fluctuations in API demand.
Competition from large pharma companies.
Currency risks due to global exposure.
Jubilant Pharmova Ltd is a promising stock in the Indian pharmaceutical sector with a balanced growth outlook. With strong fundamentals, R&D capabilities, and a healthy shareholding pattern, the company has the potential to reach ₹2,200 by 2030. For investors seeking exposure in the pharma and life sciences sector, Jubilant Pharmova can be a reliable addition to a long-term portfolio.
1. What is the current share price of Jubilant Pharmova?
The current share price is around ₹1,067 (as of August 2025).
2. Is Jubilant Pharmova a good stock to buy?
Yes, it has strong fundamentals, promoter confidence, and global presence.
3. What is Jubilant Pharmova’s share price target for 2025?
Analysts expect it between ₹1,100 – ₹1,180.
4. Can Jubilant Pharmova reach ₹2,000 by 2030?
Yes, based on growth forecasts, it may reach ₹2,200 by 2030.
5. What is the dividend yield of Jubilant Pharmova?
Currently, it offers a dividend yield of 0.47%.
6. What is Jubilant Pharmova’s 52-week high and low?
The 52-week high is ₹1,309.90 and the low is ₹802.00.
7. What is the shareholding pattern of Jubilant Pharmova?
Promoters hold 47.68%, retail 25.39%, FIIs 17.40%, mutual funds 6.01%, and others 3.52%.
8. Is Jubilant Pharmova stock volatile?
With a Beta of 0.84, it is less volatile compared to the broader market.
9. What is Jubilant Pharmova’s market capitalization?
The market cap is around ₹17,106 Cr.
10. Should I invest in Jubilant Pharmova for the long term?
Yes, it is suitable for long-term investors seeking steady growth in the healthcare sector.
???? Disclaimer: This article is for educational purposes only. Please consult a SEBI-registered financial advisor before investing.
Register & Login